{"nctId":"NCT00333840","briefTitle":"Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","startDateStruct":{"date":"2000-06"},"conditions":["Chronic Myelogenous Leukemia"],"count":1106,"armGroups":[{"label":"imatinib (STI571)","type":"EXPERIMENTAL","interventionNames":["Drug: imatinib mesilate","Drug: interferon-alpha (INF-a)","Drug: cytarabine (ARA-C)"]},{"label":"IFN-a+Ara-C","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: imatinib mesilate","Drug: interferon-alpha (INF-a)","Drug: cytarabine (ARA-C)"]}],"interventions":[{"name":"imatinib mesilate","otherNames":["Glivec®","Gleevec®","STI571"]},{"name":"interferon-alpha (INF-a)","otherNames":["Roferon®-A","Intron®-A"]},{"name":"cytarabine (ARA-C)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Must have signed consent for Amendment 5\n* Must have completed visit 62 of the core IRIS trial or be in follow-up\n* Must be on STI571 treatment\n* If on IFN treatment, must be willing to cross over to STI571 treatment\n\nExclusion criteria:\n\n* Patients who have discontinued from the study and are in follow-up\n* Patients who are on IFN treatment and do not want to cross over to STI571 treatment\n* Patients who have not consented to amendment 5\n* Patients who did not complete the amendment 5 protocol\n\nAdditional protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Kaplan-Meier Estimates of Overall Survival (All Randomized Participants)","description":"Overall survival was defined as the time between date of randomization and death due to any cause. The time was censored at last examination date for patients who were still being treated and at date of last contact for patients who discontinued treatment. Kaplan-Meier estimates of the percentage of participants at each time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"97.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.4","spread":null},{"groupId":"OG001","value":"85.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"83.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","spread":null},{"groupId":"OG001","value":"83.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null},{"groupId":"OG001","value":"81.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"79.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"78.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":null},{"groupId":"OG001","value":"77.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.3","spread":null},{"groupId":"OG001","value":"75.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan Meier Estimates of Event Free Survival (All Randomized Participants)","description":"Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment:\n\n* progression to Accelerated Phase (AP) or Blast Crisis (BC)\n* loss of Complete Hematological Response (CHR)\n* loss of Major Cytogenetic Response (MCyR) confirmed\n* loss of Major Cytogenetic Response (MCyR) unconfirmed\n* increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC)\n* death (due to any cause when reported as primary reason for discontinuation of treatment).\n\nKaplan Meier estimates of the percentage of participants with Event Free Survival at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"79.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","spread":null},{"groupId":"OG001","value":"70.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null},{"groupId":"OG001","value":"67.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null},{"groupId":"OG001","value":"63.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":null},{"groupId":"OG001","value":"61.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null},{"groupId":"OG001","value":"60.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null},{"groupId":"OG001","value":"59.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null},{"groupId":"OG001","value":"58.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.9","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null},{"groupId":"OG001","value":"51.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Event Free Survival Events (All Randomized Participants)","description":"Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment:\n\n* progression to Accelerated Phase (AP) or Blast Crisis (BC)\n* loss of Complete Hematological Response (CHR)\n* loss of Major Cytogenic Response (MCyR) confirmed\n* loss of Major Cytogenic Response (MCyR) unconfirmed\n* increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC)\n* death (due to any cause when reported as primary reason for discontinuation of treatment).\n\nThe percentage of participants with Event Free Survival events in each category was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"32.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"12.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan Meier Estimates of Time to Progression to Accelerated Phase (AP) or Blast Crisis (BC) (All Randomized Participants)","description":"Time to progression to AP/BC is defined as the time between randomization and either of the following events on treatment: death (due to CML when reported as primary reason for discontinuation of treatment) or progression to Accelerated Phase or Blast Crisis and is censored at last examination date for patients without event. No data after discontinuation of study treatment was included. The Kaplan Meier estimates of the percentage of participants with survival without progression to AP/BC at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null},{"groupId":"OG001","value":"87.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"84.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"83.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"83.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"82.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"82.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"82.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"82.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"82.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"82.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Best Cytogenetic Response (First-line Treatment)","description":"Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Philadelphia chromosome positive (Ph+) metaphases) and amount of blasts and promyelocytes in bone marrow to establish cytogenetic response.\n\nMajor Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \\> 0 and ≤ 35 % of Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.0","spread":null},{"groupId":"OG001","value":"23.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Best Cytogenetic Response (Second-line Treatment)","description":"Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Ph chromosome (Ph+) containing metaphases) and the amount of blasts and promyelocytes in bone marrow to establish cytogenetic response.\n\nMajor Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \\> 0 and ≤ 35 % Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"86.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"81.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)","description":"A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"163","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment)","description":"A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"160","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Molecular Response (First-line Treatment)","description":"Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":null},{"groupId":"OG001","value":"58.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.9","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.5","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Molecular Response (Second-line Treatment)","description":"Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":226,"n":551},"commonTop":["Nausea","Fatigue","Diarrhoea","Headache","Muscle spasms"]}}}